[Restoration of depressed immune responses by PSK in C3H/He mice bearing the syngeneic X5563 tumor]. 1986

K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto

PSK is a protein-bound polysaccharide prepared from cultured mycelium of Coriolus versicolor. The effects of PSK on immunologic responsiveness were investigated in C3H/He mice bearing syngeneic X5563 tumor. The results were as follows. elayed foot pad reaction and antibody-forming capacity to sheep erythrocytes were depressed in tumor bearing mice, and such depression was prevented by oral or intraperitoneal administration of PSK. In vitro cytotoxic activity of splenic lymphocytes against the tumor was augmented by PSK administration. Antitumor effect was augmented by combination of PSK and X-irradiation. Delayed foot pad reaction to sheep erythrocytes was suppressed in normal C3H/He mice given immunosuppressive substance obtained from tumor-bearing mice, and the depressed reaction recovered to the normal level following PSK administration. These results show that PSK is effective in the syngeneic murine tumor system.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D008297 Male Males
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
January 1992, Journal of clinical & laboratory immunology,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
January 1983, Cancer immunology, immunotherapy : CII,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
September 1977, Bollettino dell'Istituto sieroterapico milanese,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
April 1997, Immunopharmacology,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
September 1987, Journal of clinical & laboratory immunology,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
February 1983, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
April 1997, Anti-cancer drugs,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
December 1984, Journal of clinical & laboratory immunology,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
January 1978, Folia biologica,
K Matsunaga, and I Morita, and Y Oguchi, and T Fujii, and C Yoshikumi, and K Nomoto
March 1983, Immunology,
Copied contents to your clipboard!